ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Maze Therapeutics has granted Shionogi an exclusive license to its investigational Pompe disease drug 5 months after the US Federal Trade Commission stopped Maze’s similar deal with Sanofi on antitrust grounds. The FTC had complained that if Sanofi were to acquire the drug candidate, it would have gotten rid of a potential challenge to what it called Sanofi’s monopoly on drugs to treat Pompe disease, a rare condition that causes muscle weakness over time. Shionogi will pay Maze $150 million up front, with the possibility of milestone payments. The candidate, MZE001, is a glycogen synthase 1 inhibitor that Maze says blocks glycogen accumulation.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X